Swiss drug maker Santhera Pharmaceuticals Holding AG (SPHDF.OB) announced Friday that European Commission's Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion in favor of approval of AGAMREE (vamorolone) to treat Duchenne muscular dystrophy or DMD patients aged 4 years and older.